2022
Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder P, Ellenberg S, Grossmann M, Travison T, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Brock G, Tenover J, Tan H, Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Andersen M, Magnussen L, Hernández R, Oliver N, Wu F, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity 2022, 3: e381-e393. PMID: 35711614, PMCID: PMC9184259, DOI: 10.1016/s2666-7568(22)00096-4.Peer-Reviewed Original ResearchConceptsRisk of biasMeta-analysisStudy designSystematic reviewInclusion criteriaCochrane Database of Systematic ReviewsCochrane risk of bias toolDatabase of Systematic ReviewsRisk of bias toolMEDLINE In-Process & Other Non-Indexed CitationsIn-Process & Other Non-Indexed CitationsTwo-stage meta-analysisCharacteristics of interventionsOther Non-Indexed CitationsMeta-analysis of randomised controlled trialsOne-stage meta-analysisFull-text screeningRandomised controlled trialsNon-Indexed CitationsCardiovascular eventsAggregate data meta-analysisCoronary heart diseaseData meta-analysisPeer-reviewed publicationsCochrane Controlled Trials Register
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapy